Differential expression of integrin subunits in DU-145/AR prostate cancer cells.
We have established a clonal DU-145 prostate cancer cell line (DU-145/AR) stably transfected with androgen receptor cDNA. We investigated the expression of integrin subunits, adhesion to extracellular matrices, the invasion of DU-145/AR prostate cancer cells. The expression of various integrin subunits and adhesion to various extracellular matrices in DU-145, DU-145/Neo and DU-145/AR cells were examined. The haptoinvasion and the haptotactic migration of these cells were investigated using a Transwell cell culture chamber assay. DU-145/AR cells exhibited lower expression of alpha6 and beta4 integrin subunits and higher expression of alpha2 and alpha5 than DU-145 cells. DU-145/AR cells showed significantly lower adhesion to fibronectin, laminin-1 and laminin-5 than DU-145/ Neo cells, whereas DU-145/AR cells showed higher adhesion to type I and type IV collagen. Haptoinvasion of DU-145/AR cells into Matrigel/fibronectin-coated filter was significantly reduced as compared with DU-145/Neo or DU-145 cells, but there was no significant difference between DU-145/AR and control cells in the haptotactic migration to fibronectin. Dihydrotestosterone (DHT) inhibited the invasive ability of DU-145/AR cells. These results indicate that androgen receptor may play a role in the regulation of adhesion to the extracellular matrices and invasion of prostate cancer cells through influencing the expression of specific integrin subunits.
Nagakawa
Osamu
O
Department of Pathogenic Biochemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan. nagakawa@ms.toyama-mpu.ac.jp
Akashi
Takuya
T
Hayakawa
Yoshihiro
Y
Junicho
Akira
A
Koizumi
Keiichi
K
Fujiuchi
Yasuyoshi
Y
Furuya
Yuzo
Y
Matsuda
Tadashi
T
Fuse
Hideki
H
Saiki
Ikuo
I
D000728:Androgens / Q000494:pharmacology; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement; D024042:Collagen Type I / Q000378:metabolism; D024141:Collagen Type IV / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics / Q000378:metabolism; D013196:Dihydrotestosterone / Q000494:pharmacology; D005109:Extracellular Matrix; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D039421:Integrin alpha2 / Q000378:metabolism; D039482:Integrin alpha5 / Q000378:metabolism; D039503:Integrin alpha6 / Q000378:metabolism; D039663:Integrin beta4 / Q000378:metabolism; D007797:Laminin / Q000378:metabolism; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000378:metabolism*; D021122:Protein Subunits; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D000097794:Kalinin
D000728:Androgens; D015815:Cell Adhesion Molecules; D024042:Collagen Type I; D024141:Collagen Type IV; D018076:DNA, Complementary; D013196:Dihydrotestosterone; D005353:Fibronectins; D039421:Integrin alpha2; D039482:Integrin alpha5; D039503:Integrin alpha6; D039663:Integrin beta4; D007797:Laminin; D021122:Protein Subunits; D011944:Receptors, Androgen; D000097794:Kalinin; C121346:laminin 1